<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00406744</url>
  </required_header>
  <id_info>
    <org_study_id>APEC-0012</org_study_id>
    <nct_id>NCT00406744</nct_id>
  </id_info>
  <brief_title>Efficacy of Retreatments With Intravitreal Bevacizumab</brief_title>
  <official_title>Evaluation of Efficacy of Intravitreal Bevacizumab Retreatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociación para Evitar la Ceguera en México</source>
  <brief_summary>
    <textblock>
      Choroidal neovascularization is a leading cause of visual loss in people older than 60 years
      and for its treatment there had been performed multicentric studies with Lucentis
      (Ranibizumab) with a significant improval of visual acuity. In our institution we evaluated
      efficacy of bevacizumab in several pathologies but we dont know what would be the results if
      we use the same dose several times. Our purpose was to determine the efficacy of bevacizumab
      for improve or stabilize visual acuity with two or more intravitreal inyections of
      bevacizumab.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2006</start_date>
  <completion_date>November 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity, OCT foveal thickness and fluorescein angiogram</measure>
  </primary_outcome>
  <enrollment>20</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <condition>Choroidal Neovascularization</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal injection of Bevacizumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  * Any visual acuity

               -  OCT: Central foveal thickness greater than 300 u or with evidence of subretinal
                  fluid.

               -  Active angiogram leakage

        Exclusion Criteria:

          -  * Basal Inflammatory disease

               -  Endoftalmitis history

               -  Lesions bigger than 5400 u or with scarring greater than 50% of lesion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronica Kon-Jara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APEC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veronica A Kon-Jara, MD</last_name>
    <phone>525510841400</phone>
    <phone_ext>1172</phone_ext>
    <email>veronicakon@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hugo Quiroz-Mercado, MD</last_name>
    <phone>525510841400</phone>
    <phone_ext>1171</phone_ext>
    <email>retinamex@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asociacion para Evitar la Ceguera en Mexico</name>
      <address>
        <city>Mexico DF</city>
        <state>DF</state>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Kon-Jara, MD</last_name>
      <phone>525510841400</phone>
      <phone_ext>1171</phone_ext>
      <email>veronicakon@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Veronica Kon-Jara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mitzy Torres-Soriano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Luis Diaz-Rubio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Myriam Hernandez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hugo Quiroz-Mercado, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>November 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2006</study_first_submitted>
  <study_first_submitted_qc>November 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2006</study_first_posted>
  <last_update_submitted>November 30, 2006</last_update_submitted>
  <last_update_submitted_qc>November 30, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2006</last_update_posted>
  <keyword>neovascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

